Pfizer Inc. (NYSE:PFE) Stock Position Cut by First Long Island Investors LLC

First Long Island Investors LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 1.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 405,865 shares of the biopharmaceutical company’s stock after selling 4,630 shares during the period. Pfizer makes up 2.6% of First Long Island Investors LLC’s portfolio, making the stock its 10th largest holding. First Long Island Investors LLC’s holdings in Pfizer were worth $17,716,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Clarius Group LLC increased its position in Pfizer by 34.2% in the 4th quarter. Clarius Group LLC now owns 17,689 shares of the biopharmaceutical company’s stock valued at $772,000 after acquiring an additional 4,504 shares during the period. Smart Portfolios LLC increased its position in Pfizer by 12.5% in the 4th quarter. Smart Portfolios LLC now owns 4,428 shares of the biopharmaceutical company’s stock valued at $193,000 after acquiring an additional 493 shares during the period. Lyell Wealth Management LP increased its position in Pfizer by 1.3% in the 4th quarter. Lyell Wealth Management LP now owns 94,406 shares of the biopharmaceutical company’s stock valued at $4,121,000 after acquiring an additional 1,220 shares during the period. Moneta Group Investment Advisors LLC increased its position in Pfizer by 4.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 75,052 shares of the biopharmaceutical company’s stock valued at $3,276,000 after acquiring an additional 3,246 shares during the period. Finally, Clearstead Advisors LLC increased its position in shares of Pfizer by 4.5% during the fourth quarter. Clearstead Advisors LLC now owns 111,352 shares of the biopharmaceutical company’s stock worth $4,861,000 after buying an additional 4,809 shares during the period. 71.83% of the stock is owned by hedge funds and other institutional investors.

PFE has been the subject of several recent analyst reports. Morgan Stanley initiated coverage on shares of Pfizer in a research report on Tuesday, June 4th. They set an “overweight” rating and a $48.00 price objective for the company. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, April 30th. Credit Suisse Group reiterated a “buy” rating and set a $48.00 price objective on shares of Pfizer in a research report on Monday, June 17th. Zacks Investment Research cut shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. Finally, Bank of America increased their price objective on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Thirteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $46.22.

NYSE PFE traded up $0.45 during trading hours on Monday, reaching $43.77. 20,234,126 shares of the company were exchanged, compared to its average volume of 23,956,598. Pfizer Inc. has a 1 year low of $36.00 and a 1 year high of $46.47. The firm has a 50 day simple moving average of $42.48. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60. The company has a market cap of $243.36 billion, a PE ratio of 14.59, a P/E/G ratio of 2.51 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The business had revenue of $13.12 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter last year, the company posted $0.77 earnings per share. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.88 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be issued a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a yield of 3.29%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

In related news, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $850,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the sale, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What is the Coverage Ratio?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.